Table 3.
Pharmaceutical target of inflammasome in cancer.
| Therapeutic agents (Trade name) | Targets | Mechanisms of action | Cancer type | Status | Ref. |
|---|---|---|---|---|---|
| Anakinra (Kineret) | IL-1 receptor | IL-1R antagonist | Metastatic breast cancer | Phase I | NCT01802970 |
| Anakinra (Kineret) | IL-1 receptor | IL-1R antagonist | Metastatic CRC | Phase II | NCT02090101 |
| Anakinra (Kineret) | IL-1 receptor | IL-1R antagonist | Multiple myeloma & plasma cell neoplasm | Phase II | NCT00635154 |
| Canakinumab (Ilaris) | IL-1β | Anti-IL-1β monoclonal antibody | CRC, triple-negative breast cancer, NSCLC | Phase I | NCT02900664 |
| Gevokizumab | IL-1β | Anti-IL-1β monoclonal antibody | Metastatic CRC, gastroesophageal cancer, renal cell carcinoma | Phase I | NCT03798626 |
| MCC950 | NLRP3 inflammasome | Inhibition of ASC oligomerization | Head and neck squamous cell carcinoma | Preclinical | 139 |
| Oxidized ATP | P2X7 receptor | Selective P2X7 antagonist | P2X7-expressing tumors, melanoma | NA | 139,140 |